Notwithstanding any other provision of law, a health insurance issuer or a contracted utilization review organization may not require a prior authorization for drug therapies approved by the U.S. Food and Drug Administration for the treatment of hereditary bleeding disorders more frequently than every 6 months or the length of time the prescription for that dosage remains valid, whichever period is shorter.
215 ILCS 200/77
Prior authorization for drug therapies for hereditary bleeding disorders
Known as the Prior Authorization Reform Act
The act spans §§ 215-200-1 to 215-200-999 (23 sections).
P.A. 103-659, eff. 1-1-26; 104-417, eff. 8-15-25.
Official source: Illinois General Assembly. Reproduced from public-domain Illinois statutes; confirm against the official source for the current text. Not legal advice.